Diaceutics Plc provides data analytics and implementation services for pharmaceutical companies worldwide.
Reasonable growth potential with adequate balance sheet.
Share Price & News
How has Diaceutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 7DC's share price has been volatile over the past 3 months.
7 Day Return
DE Life Sciences
1 Year Return
DE Life Sciences
Return vs Industry: 7DC exceeded the German Life Sciences industry which returned 29.7% over the past year.
Return vs Market: 7DC exceeded the German Market which returned -13.1% over the past year.
Price Volatility Vs. Market
How volatile is Diaceutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Diaceutics undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 7DC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 7DC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 7DC is poor value based on its PE Ratio (221.8x) compared to the Life Sciences industry average (52.8x).
PE vs Market: 7DC is poor value based on its PE Ratio (221.8x) compared to the German market (17.4x).
Price to Earnings Growth Ratio
PEG Ratio: 7DC is poor value based on its PEG Ratio (4.1x)
Price to Book Ratio
PB vs Industry: 7DC is overvalued based on its PB Ratio (4.8x) compared to the XE Life Sciences industry average (3.9x).
How is Diaceutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 7DC's forecast earnings growth (54.1% per year) is above the savings rate (-0.4%).
Earnings vs Market: 7DC's earnings (54.1% per year) are forecast to grow faster than the German market (14.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 7DC's revenue (18.9% per year) is forecast to grow faster than the German market (3.9% per year).
High Growth Revenue: 7DC's revenue (18.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 7DC's Return on Equity is forecast to be high in 3 years time
How has Diaceutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 7DC has a high level of non-cash earnings.
Growing Profit Margin: 7DC's current net profit margins (3%) are lower than last year (6.1%).
Past Earnings Growth Analysis
Earnings Trend: 7DC's earnings have grown by 0.2% per year over the past 5 years.
Accelerating Growth: 7DC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 7DC had negative earnings growth (-37.1%) over the past year, making it difficult to compare to the Life Sciences industry average (-1.1%).
Return on Equity
High ROE: 7DC's Return on Equity (2%) is considered low.
How is Diaceutics's financial position?
Financial Position Analysis
Short Term Liabilities: 7DC's short term assets (£18.4M) exceed its short term liabilities (£2.2M).
Long Term Liabilities: 7DC has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 7DC's debt to equity ratio (0.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 7DC's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 7DC's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 7DC's interest payments on its debt are well covered by EBIT (8.5x coverage).
What is Diaceutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 7DC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 7DC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 7DC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 7DC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 7DC's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Peter Keeling serves as Chief Executive Officer and Director of Diaceutics PLC. Mr. Keeling was Co-founder and Chief Executive at Diagnology Limited.
|CEO & Director||no data||no data||25.19% £27.5m|
|CFO, Company Secretary & Director||no data||no data||4.35% £4.7m|
|Chief Operating Officer||no data||no data||no data|
|Chief Technical Officer||no data||no data||no data|
|General Counsel||0.92yr||no data||no data|
|Chief Innovation Officer & Director||no data||no data||4.15% £4.5m|
|Head of Strategic Alliances||0.25yr||no data||no data|
|Managing Director||1.25yrs||no data||no data|
|Head of Global Data||0.67yr||no data||no data|
|Managing Director||0.67yr||no data||no data|
Experienced Management: 7DC's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 323326.8%.
Diaceutics PLC's company bio, employee growth, exchange listings and data sources
- Name: Diaceutics PLC
- Ticker: 7DC
- Exchange: DB
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£95.677m
- Listing Market Cap: UK£108.993m
- Shares outstanding: 69.58m
- Website: https://www.diaceutics.com
Number of Employees
- Diaceutics PLC
- Titanic Suites
- Enterprise House
- County Antrim
- BT2 8FE
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|7DC||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Mar 2019|
|DXRX||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Mar 2019|
Diaceutics Plc provides data analytics and implementation services for pharmaceutical companies worldwide. It offers diagnostic landscape services, such as patient journey, lab mapping, diagnostic regulation, turnaround time, and sample availability analysis services; diagnostic tracking services, including lab tracking, patient insights, and physician segmentation services; and diagnostic payers research, diagnostic clinical landscape, integrated mapping research, buying process research, and testers/non-testers research services. The company also provides diagnostic planning services consisting of strategic and technical planning, launch planning, diagnostic partner selection, and financial forecast services; commercialization services comprising content creation, workshops, diagnostic adboards, conference support, and proficiency testing services; and reimbursement services. The company is based in Belfast, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/10 00:04|
|End of Day Share Price||2020/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.